Nimrata Hunt - 07 Nov 2025 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Signature
/s/ Lily J. Lu, Attorney-in-Fact for Nimrata Hunt
Issuer symbol
IDXX
Transactions as of
07 Nov 2025
Net transactions value
-$1,839,066
Form type
4
Filing time
10 Nov 2025, 17:01:13 UTC
Previous filing
13 Aug 2025
Next filing
17 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hunt Nimrata Executive Vice President ONE IDEXX DRIVE, WESTBROOK /s/ Lily J. Lu, Attorney-in-Fact for Nimrata Hunt 10 Nov 2025 0001800619

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDXX Common Stock Options Exercise $2,057,558 +7,125 +39% $288.78 25,169 07 Nov 2025 Direct F1
transaction IDXX Common Stock Options Exercise $2,732,390 +5,405 +21% $505.53 30,574 07 Nov 2025 Direct
transaction IDXX Common Stock Sale $3,591,059 -5,114 -17% $702.20 25,460 07 Nov 2025 Direct F2
transaction IDXX Common Stock Sale $1,030,970 -1,465 -5.8% $703.73 23,995 07 Nov 2025 Direct F3
transaction IDXX Common Stock Sale $1,034,743 -1,468 -6.1% $704.87 22,527 07 Nov 2025 Direct F4
transaction IDXX Common Stock Sale $972,241 -1,378 -6.1% $705.54 21,149 07 Nov 2025 Direct F5
holding IDXX Common Stock 160 07 Nov 2025 jointly with spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDXX Non-Qualified Stock Option (right-to-buy) Options Exercise $0 -7,125 -100% $0.000000 0 07 Nov 2025 Common Stock 7,125 $288.78 Direct F6
transaction IDXX Non-Qualified Stock Option (right-to-buy) Options Exercise $0 -5,405 -77% $0.000000 1,604 07 Nov 2025 Common Stock 5,405 $505.53 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 11 shares purchased under the Issuer Employee Stock Purchase Plan on September 30, 2025.
F2 Represents the weighted average price of the shares sold ranging from a low of $702.00 to a high of $703.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F3 Represents the weighted average price of the shares sold ranging from a low of $703.05 to a high of $703.97 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F4 Represents the weighted average price of the shares sold ranging from a low of $704.235 to a high of $705.175 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F5 Represents the weighted average price of the shares sold ranging from a low of $705.26 to a high of $705.92 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F6 Grant of option to buy shares of Issuer common stock that vested in four annual installments beginning February 14, 2021.
F7 Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2023.